Your browser doesn't support javascript.
loading
Using bioinformatics approaches to investigate driver genes and identify BCL7A as a prognostic gene in colorectal cancer.
Chao, Jeffrey Yung-Chuan; Chang, Hsin-Chuan; Jiang, Jeng-Kai; Yang, Chih-Yung; Chen, Fang-Hsin; Lai, Yo-Liang; Lin, Wen-Jen; Li, Chia-Yang; Wang, Shu-Chi; Yang, Muh-Hwa; Lin, Yu-Feng; Cheng, Wei-Chung.
Afiliação
  • Chao JY; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Chang HC; Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Jiang JK; Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Yang CY; Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Chen FH; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Lai YL; Department of Teaching and Research, Taipei City Hospital, Taipei, Taiwan.
  • Lin WJ; Commission for General Education, National United University, Miaoli, Taiwan.
  • Li CY; General Education Center, University of Taipei, Taipei, Taiwan.
  • Wang SC; Department of Medical Imaging and Radiological Sciences, Chang Gung University, Taoyuan, Taiwan.
  • Yang MH; Department of Radiation Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
  • Lin YF; Institute for Radiological Research, Chang Gung University and Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Cheng WC; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.
Comput Struct Biotechnol J ; 19: 3922-3929, 2021.
Article em En | MEDLINE | ID: mdl-34306573
ABSTRACT
Colorectal cancer (CRC) results from the uncontrolled growth of cells in the colon, rectum, or appendix. The 5-year relative survival rate for patients with CRC is 65% and is correlated with the stage at diagnosis (being 91% for stage I at diagnosis versus 12% for stage IV). This study aimed to identify CRC driver genes to assist in the design of a cancer panel to detect gene mutations during clinical early-stage screening and identify genes for use in prognostic assessments and the evaluation of appropriate treatment options. First, we utilized bioinformatics approaches to analyze 354 paired sequencing profiles from The Cancer Genome Atlas (TCGA) to identify CRC driver genes and analyzed the sequencing profiles of 38 patients with >5 years of follow-up data to search for prognostic genes. The results revealed eight driver genes and ten prognostic genes. Next, the presence of the identified gene mutations was verified using tissue and blood samples from Taiwanese CRC patients. The results showed that the set identified gene mutations provide high coverage for driver gene screening, and APC, TP53, PIK3CA, and FAT4 could be detected in blood as ctDNA test targets. We further found that BCL7A gene mutation was correlated with prognosis in CRC (log-rank p-value = 0.02), and that mutations of BCL7A could be identified in ctDNA samples. These findings may be of value in clinical early cancer detection, disease monitoring, drug development, and treatment efforts in the future.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article